Medivir begins Phase I trial of AL-704 to treat hepatitis C
AL-704 is a nucleotide based NS5B polymerase inhibitor also known as JNJ-54257099, by Alios Biopharma, part of the Janssen Pharmaceutical Companies. It is intended for the treatment of
AL-704 is a nucleotide based NS5B polymerase inhibitor also known as JNJ-54257099, by Alios Biopharma, part of the Janssen Pharmaceutical Companies. It is intended for the treatment of
The IND acceptance allows the company to start an open-label Phase I trial designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML
FX006 is a new, non-opioid, sustained-release, intra-articular (IA) (within the joint) formulation of triamcinolone acetonide (TCA) designed to treat patients with moderate to severe osteoarthritis (OA) pain of
Mogamulizumab is a new, humanized mAb directed against CC chemokine receptor type 4 (CCR4). Opdivo is a PD-1 immune checkpoint inhibitor that has received approval from the US
ZS-9 is an insoluble, non-absorbed zirconium silicate with a three-dimensional crystalline lattice structure that was designed to preferentially trap potassium ions. The potassium selectivity of ZS-9 allows high
The breakthrough status was based on the results from a Phase II clinical trial (Study 205) of lenvatinib in advanced or metastatic renal cell carcinoma following one prior
The multicenter, open-label treatment-optimized, double-blind, randomized, placebo-controlled, forced-withdrawal, parallel group Phase III trial is expected to generate top-line data by year-end. HLD200 is a new delayed and extended
The company noted that anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, an important cancer stem cell pathway identified by OncoMed researchers. In
Currently, Azedra is being evaluated in a pivotal Phase IIb trial, which is being conducted under a Special Protocol Assessment Agreement (SPA), and has received orphan drug and
Reslizumab is designed to treat inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen. The MAA is based on data from